First licensed treatment for hidradenitis suppurativa

The licence for Humira (adalimumab) has been extended to include the treatment of active moderate to severe hidradenitis suppurativa (HS) in adults who have had an inadequate response to conventional HS therapy

HS is a painful, chronic systemic inflammatory disorder, characterised by inflamed nodules, boils and abscesses located particularly around the groin and underarm.
‘The approval of Humira to treat moderate to severe HS is a major step forward in supporting patients with this distressing and life-changing condition,’ said Dr David Fitzgerald, consultant dermatologist at Salford Royal NHS Foundation Trust. ‘Patients with HS can experience immense pain and the condition often dramatically affects their psychological wellbeing and quality of life.’
The benefits and risks of long-term treatment should be regularly evaluated and if treatment is interrupted, Humira may be reintroduced at the maintenance dose of 40mg per week.
Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Topical Steroids, Comparison of Potencies and Formulations

Topical Steroids, Comparison of Potencies and Formulations

Strengths and formulations of topical steroids.

Topical Steroids, Potential Skin Sensitisers as Ingredients

Topical Steroids, Potential Skin Sensitisers as Ingredients

Potential sensitising agents in topical steroids.

Correct vitamin D deficiency to reduce COPD exacerbations, say researchers

Correct vitamin D deficiency to reduce COPD exacerbations, say researchers

Vitamin D supplements could nearly halve the rate of...

Launch of new SGLT2 inhibitor increases choice in diabetes prescribing

Launch of new SGLT2 inhibitor increases choice in diabetes prescribing

Ertugliflozin (Steglatro) is a sodium glucose co-transporter...